Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentaries

In Pursuit of a Biomarker of Weight Gain Susceptibility—Is FGF21 a Candidate?

  1. Leanne M. Redman⇑ and
  2. Eric Ravussin
  1. Division of Clinical Sciences, Pennington Biomedical Research Center, Baton Rouge, LA
  1. Corresponding author: Leanne M. Redman, leanne.redman{at}pbrc.edu
Diabetes 2019 Feb; 68(2): 266-267. https://doi.org/10.2337/dbi18-0038
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

In our westernized obesogenic environment plagued by an overabundance of calorie-dense food and physical inactivity, obesity has become a highly prevalent condition and a major concern to public health. Interestingly, the predisposition for weight gain varies among people despite similar environmental exposures or familial traits (1). While eating less and moving more are obvious remedies for obesity, such therapeutic strategies often fall short of what is expected from affected patients. Many claim that the obesity epidemic should be tackled by prevention, especially if a simple clinical test or established biomarker can identify individuals with a high susceptibility for weight gain.

Individuals who are able to withstand periods of energy excess and resist weight gain are thought to ignite a thermogenic response (an “adaptive” increase in energy expenditure), thus dissipating some of the excess energy consumed as heat rather than storing it as body fat. This hypothesis was first suggested by Neuman in 1902, who coined the term “luxuskonsumption” (2), and was reaffirmed by Stock almost 100 years later (3). In an elegant series of studies using a respiratory chamber, the group from the National Institute of Diabetes and Digestive and Kidney Diseases in Phoenix showed that in response to acute (24-h) fasting or overfeeding, individuals respond differently in decreasing or increasing 24-h energy expenditure, thus identifying individuals with a “thrifty” or “spendthrift” metabolism, respectively (4). Such metabolic phenotypes were associated with variation in weight loss during an 8-week controlled caloric restriction (5) or with spontaneous changes in weight over a 6-month follow-up period (6). However, measuring induction of adaptive thermogenesis in response to fasting or overfeeding requires a room calorimeter, a technology seldom available in research facilities and nonexistent in clinical settings.

In their latest study published in this issue of Diabetes, using an acute low-protein overfeeding dietary paradigm, Vinales et al. (7) identify the increase in fibroblast growth factor 21 (FGF21) concentrations as a potential hormonal biomarker of weight gain susceptibility. More specifically, the authors observe that ingestion of a low-protein diet (3% of total intake) that provides twice the amount of energy required for weight maintenance causes almost an average threefold increase in FGF21. Importantly, the increase in FGF21 is positively associated with the increase in 24-h energy expenditure (adaptive thermogenesis) and inversely to the spontaneous weight change (varying from −7.5 to +17.5 kg) over a 6-month follow-up period. In other words, individuals who failed to significantly increase FGF21 in response to acute overfeeding with low protein gain the most weight during the follow-up. Remarkably, the measured increase in FGF21 is robust and not influenced by the remaining diet composition (i.e., high fat or high carbohydrate). The authors therefore propose that the acute response to 24-h overfeeding with a low-protein diet can identify individuals with a “thrifty” metabolism and therefore prone to weight gain versus those with a “spendthrift” metabolism and less likely to gain weight (Fig. 1).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

The hypothesized relationship between energy expenditure, FGF21, and body weight regulation. Stimulating energy expenditure with acute low-protein overfeeding can identify individuals who are able to dissipate the excess calories consumed as heat (“spendthrift”) versus those who cannot (“thrifty”). The magnitude of the increase in plasma concentration of FGF21 in response to acute low-protein overfeeding is positively associated with the acute change in 24-h energy expenditure. Thrifty individuals have an attenuated increase in FGF21 in response to acute low-protein overfeeding and are more susceptible to weight gain over 6 months.

FGF21 is a complex and multifunctional circulatory protein that clearly operates in pathways involved in metabolic regulation throughout the body. Since the impact of FGF21 on energy metabolism is not fully understood (8), it is now imperative to investigate the physiological effects of FGF21 on energy balance. Recent gain- or loss-of-function studies in rodent models have identified compelling roles for FGF21 in the regulation of energy balance, body weight regulation, lipid homeostasis, glucose homeostasis, ketogenesis, lipolysis, and hepatic steatosis (9). However, more than 10 years after the discovery of the importance of FGF21 in weight regulation in rodents, not much progress has been made to test its role in human obesity and whether it represents a potential pharmacological target for weight management.

Longitudinal studies in Pima Indians have clearly shown that weight gain susceptibilty is associated with factors related to energy metabolism, such as low metabolic rate (10), low rates of fat oxidation (11), low levels of spontaneous physical activity (12), and low sympathetic nervous system activity (13). However, surprisingly, Vinales et al. (7) report that only the acute change in FGF21 was a potential predictor of weight change over 6 months, whereas the acute change in 24-h energy expenditure was not in the present data set. As acknowledged by the authors, the small sample size is a limitation of the current study. Another limitation is the lack of measurement of physical fitness (VO2max), an important physiological trait known to be associated with metabolic flexibility and metabolic health. Finally, it is worth noting that the weight gain in this study was nonhabitual (>5 kg) for some individuals over 6 months. Clearly, this work instigates future explorations into 1) the use of an acute protein overfeeding paradigm as a “metabolic stress test” for identifying potential biomarkers of weight gain susceptibility and 2) the potential of FGF21 as a biomarker for predicting weight gain and a therapeutic remedy for obesity in humans. As a next step, it is imperative that a controlled overfeeding study be conducted to investigate the hypothesized greater weight gain in those with lower increase in FGF21 in response to acute low-protein overfeeding. Only such studies will tell us whether FGF21 can be reliably used as a biomarker of weight gain susceptibility in humans.

Article Information

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying article, p. 318.

  • © 2019 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. Stunkard AJ,
    2. Sørensen TI,
    3. Hanis C, et al
    . An adoption study of human obesity. N Engl J Med 1986;314:193–198pmid:3941707
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Neumann RO
    . Experimentelle beiträge zur lehre von dem täglichen nahrungsbedarf des menschen unter besonderer beruck-sichtigung der notwendigen eiweissmenge. Arch Hyg 1902;45:1–87
    OpenUrl
  3. ↵
    Stock MJ. Gluttony and thermogenesis revisited. Int J Obes Relat Metab Disord 1999;23:1105–1117
  4. ↵
    Weyer C, Vozarova B, Ravussin E, Tataranni PA. Changes in energy metabolism in response to 48 h of overfeeding and fasting in Caucasians and Pima Indians. Int J Obes Relat Metab Disord 2001;25:593–600
  5. ↵
    1. Reinhardt M,
    2. Thearle MS,
    3. Ibrahim M, et al
    . A human thrifty phenotype associated with less weight loss during caloric restriction. Diabetes 2015;64:2859–2867pmid:25964395
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Schlögl M,
    2. Piaggi P,
    3. Pannacciuli N,
    4. Bonfiglio SM,
    5. Krakoff J,
    6. Thearle MS
    . Energy expenditure responses to fasting and overfeeding identify phenotypes associated with weight change. Diabetes 2015;64:3680–3689pmid:26185280
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Vinales KL,
    2. Begaye B,
    3. Bogardus C,
    4. Walter M,
    5. Krakoff J,
    6. Piaggi P
    . FGF21 is a hormonal mediator of the human “thrifty” metabolic phenotype. Diabetes 2019;68:318–323
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Kharitonenkov A,
    2. Shiyanova TL,
    3. Koester A, et al
    . FGF-21 as a novel metabolic regulator. J Clin Invest 2005;115:1627–1635pmid:15902306
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Owen BM,
    2. Ding X,
    3. Morgan DA, et al
    . FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab 2014;20:670–677pmid:25130400
    OpenUrlCrossRefPubMed
  10. ↵
    1. Ravussin E,
    2. Lillioja S,
    3. Knowler WC, et al
    . Reduced rate of energy expenditure as a risk factor for body-weight gain. N Engl J Med 1988;318:467–472pmid:3340128
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Zurlo F,
    2. Lillioja S,
    3. Esposito-Del Puente A, et al
    . Low ratio of fat to carbohydrate oxidation as predictor of weight gain: study of 24-h RQ. Am J Physiol 1990;259:E650–E657pmid:2240203
    OpenUrlPubMedWeb of Science
  12. ↵
    1. Zurlo F,
    2. Ferraro RT,
    3. Fontvielle AM,
    4. Rising R,
    5. Bogardus C,
    6. Ravussin E
    . Spontaneous physical activity and obesity: cross-sectional and longitudinal studies in Pima Indians. Am J Physiol 1992;263:E296–E300pmid:1514610
    OpenUrlPubMedWeb of Science
  13. ↵
    1. Tataranni PA,
    2. Young JB,
    3. Bogardus C,
    4. Ravussin E
    . A low sympathoadrenal activity is associated with body weight gain and development of central adiposity in Pima Indian men. Obes Res 1997;5:341–347pmid:9285842
    OpenUrlPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Diabetes: 68 (2)

In this Issue

February 2019, 68(2)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In Pursuit of a Biomarker of Weight Gain Susceptibility—Is FGF21 a Candidate?
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
In Pursuit of a Biomarker of Weight Gain Susceptibility—Is FGF21 a Candidate?
Leanne M. Redman, Eric Ravussin
Diabetes Feb 2019, 68 (2) 266-267; DOI: 10.2337/dbi18-0038

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

In Pursuit of a Biomarker of Weight Gain Susceptibility—Is FGF21 a Candidate?
Leanne M. Redman, Eric Ravussin
Diabetes Feb 2019, 68 (2) 266-267; DOI: 10.2337/dbi18-0038
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Going in Early: Hypoxia as a Target for Kidney Disease Prevention in Diabetes?
  • There Is Something About Insulin Granules
  • Metabolic Flexibility of Mitochondria Plays a Key Role in Balancing Glucose and Fatty Acid Metabolism in the Diabetic Heart
Show more Commentaries

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.